US 11,813,252 B2
Treatment for Parkinson's disease
Nitin Krishnaji Damle, Mumbai (IN); Sanjay Nandlalji Mandhane, Baroda (IN); Manoj Atmaramji Upadhya, Baroda (IN); Sameer Vishwanath Mehetre, Baroda (IN); Gajanan Uttamrao Chidrewar, Baroda (IN); Prabal Sengupta, Baroda (IN); and Trinadha Rao Chitturi, Baroda (IN)
Assigned to SUN PHARMA ADVANCED RESEARCH COMPANY LTD., Mumbai (IN)
Filed by SUN PHARMA ADVANCED RESEARCH COMPANY LTD., Mumbai (IN)
Filed on May 18, 2022, as Appl. No. 17/747,472.
Application 17/747,472 is a continuation of application No. 17/061,139, filed on Oct. 1, 2020, granted, now 11,583,522.
Application 17/061,139 is a continuation of application No. 16/304,914, granted, now 10,849,887, issued on Dec. 1, 2020, previously published as PCT/IN2017/050224, filed on Jun. 2, 2017.
Claims priority of application No. 201621019087 (IN), filed on Jun. 2, 2016; and application No. 201621019185 (IN), filed on Jun. 2, 2016.
Prior Publication US 2022/0273632 A1, Sep. 1, 2022
Int. Cl. A61K 31/44 (2006.01); A61P 25/16 (2006.01); A61K 31/47 (2006.01)
CPC A61K 31/44 (2013.01) [A61K 31/47 (2013.01); A61P 25/16 (2018.01)] 4 Claims
OG exemplary drawing
 
1. A method of treating Parkinson's disease in a subject comprising administering a therapeutically effective amount of a compound of Formula I

OG Complex Work Unit Chemistry
wherein, R1 is —NHC(O) C3-6 cycloalkyl and R2 is hydrogen;
or R1 and R2 along with the carbon atoms to which they are attached form a six membered aromatic ring, wherein the ring is substituted with one or more groups selected from hydrogen, halogen and C1-6 alkyl;
R3 and R4 are independently selected from group comprising hydrogen, halogen, C1-3 alkyl, OC1-3 alkyl, NO2, SC1-3 alkyl, C1-3 haloalkyl, OC1-3 haloalkyl, and SC1-3 haloalkyl, and wherein the compound of Formula I exhibits a ratio of concentration in brain to concentration in plasma of more than 0.15, and does not result in change in QT interval in the subject.